← Leaderboards
Sheng Cai
Sloan-Kettering Inst Can Research
$1,444,218
Attributed
$1,868,255
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $848.1K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,868,255 · 2
By mechanism
K08$1,020,180 · 1
UG1$848,075 · 1
Top collaborators
- Ross L Levine1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Jason S Lewis$26,024,327
- Omar Abdel-Wahab$18,758,829
- Ross L Levine$31,715,816
- Raajit Rampal$5,822,249
Others in their field
Other Emerging Leaders on “Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,967,203
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,728,591
- Crystal Mackall · Children'S Hosp Of Philadelphia$13,752,686
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,170,219
- Geoffrey Roger Hill · Fred Hutchinson Cancer Center$10,343,043
Research focus
LeukemiaSamplingResponseBiological MarkersHematologic NeoplasmsBiologyMolecularResearch PersonnelAcute Myeloid Leukemia CellCell DeathChemotherapyAmalgamBcl2 GeneBh3 DomainChromosomal InstabilityAzacitidineBiomarker ValidationAttenuatedAcute Myelocytic LeukemiaBloodBurden Of IllnessCareer DevelopmentBackApoptotic
Grant awards (5)
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$848,075
UG1 · FY2025 · CA
Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies$255,045
K08 · FY2024 · CA · contact PI
Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies$255,045
K08 · FY2023 · CA · contact PI
Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies$255,045
K08 · FY2022 · CA · contact PI
Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies$255,045
K08 · FY2021 · CA · contact PI